

**Proliferation of banned drugs in the country**

3177. SHRI ANIL DESAI:

SHRI SANJAY RAUT:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether there is a menace of proliferation of such drugs in India which are banned in developed countries;

(b) whether India is a large market for drug companies where the regulatory norms are poorly implemented;

(c) whether drug firms get away easily even if something goes wrong;

(d) the average compensation paid for a clinical trial death in India; and

(e) the precautionary measures Government is taking to strengthen and expand the regulatory system?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI GHULAM NABI AZAD): (a) No. Drugs are permitted for manufacture and sale in the country only after due assessment of their safety and efficacy.

(b) and (c) No.

(d) The compensations paid for deaths in clinical trials in the country during the last 2 years range from 0.5 lakh to 20 lakh.

(e) Law making is an evolving process which takes care of the emerging situations through amendments or making of new laws with the passage of time. The Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945 have been amended as and when considered necessary. The Government has also given due attention to strengthening of the drug control infrastructure of the country. As many as 216 additional posts in CDSCO have been created since 2008. The Central drug testing labs have been given new and sophisticated equipments. A new Centrally Sponsored Scheme for providing assistance to the States/UTs for strengthening of States' drug regulatory system during the Twelfth Five Year Plan has also been initiated.

**Regulatory mechanism for health sector**

3178. SHRI MANSUKH L. MANDAVIYA:

SHRI PARSHOTTAM KHODABHAI RUPALA:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state: